Latest Headlines

Latest Headlines

GlaxoSmithKline's melanoma combo beats Roche's Zelboraf in Phase III

GlaxoSmithKline is touting stellar Phase III results for an in-development combo therapy for melanoma, saying its treatment beat out Roche's Zelboraf in overall survival and led independent advisers to recommend an early end for the study.

UPDATED: GlaxoSmithKline gains FDA OK on two genetically targeted melanoma drugs

In an important win for GlaxoSmithKline's R&D division, the FDA today announced that it has approved a pair of genetically targeted melanoma drugs, dabrafenib and trametinib, from the company, along with a diagnostic test that can be used to identify the patients most likely to respond to the treatments.

GlaxoSmithKline shoots for combo attack against melanoma in surgery patients

GlaxoSmithKline has stepped up its late-stage program to advance a combo of targeted cancer drugs against deadly skin cancer, with a new study to see whether its experimental BRAF and MEK inhibitors can keep melanoma from coming back after surgeries.

GSK races to regulators for approvals of new skin cancer drugs

The drug giant's quick work with the experimental drugs shows how fast a company can get to a new drug application with treatments for well-defined groups of patients and impressive clinical data.

UPDATED: GSK aces pivotal studies for pair of melanoma drugs

Look out Roche. Because here comes GlaxoSmithKline touting upbeat results of two Phase III studies of the targeted drugs dabrafenib and trametinib in patients with metastatic melanoma.

GSK lands one-two punch in melanoma trial

Data from the small mid-stage trial provide early evidence that GSK's two-drug combo could have an edge over Roche's approved melanoma drug Zelboraf.

Cancer drug experts brace for ASCO abstract dump tonight

ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.